# DESCRIPTION

## STATEMENT OF GOVERNMENT RIGHTS

- disclose government rights

## BACKGROUND

- introduce influenza B viruses
- describe genetic variation
- discuss vaccine development
- classify influenza viruses
- summarize vaccine history

## SUMMARY

- introduce influenza B virus mutations
- describe enhanced viral titers and HA yields
- motivate reassortant or recombinant parental influenza B viruses
- summarize virus libraries generation
- identify growth-enhancing mutations
- describe strategies for developing influenza B viruses
- combine growth-enhancing residues and nucleotides
- provide isolated recombinant influenza B viruses
- describe enhanced growth in cells and eggs
- specify amino acid residues in NP, M, PA, and NS
- describe recombinant influenza B virus with enhanced growth
- summarize optional selected amino acid residues
- define reassortant influenza B virus
- describe enhanced growth in cells
- specify amino acid residues in PB2
- specify amino acid residues in HA1 and HA2
- specify amino acid residues in NA
- describe recombinant influenza B virus with internal gene segments
- specify amino acid residues in PA, PB1, PB2, NP, M1, and/or NS1
- describe conservative amino acid substitutions
- describe combinations of selected amino acid residues
- describe viral segments for PA, NP, M, and/or NS
- describe reassortant vaccine viruses
- summarize invention
- motivate enhanced growth of influenza viruses
- describe method to select for influenza viruses
- introduce influenza virus vectors
- describe vectors for vRNA or cRNA production
- describe vectors for mRNA production
- specify titers of reassortant viruses
- define substantially the same activity
- describe isolated and/or purified nucleic acid molecule
- introduce heterologous gene or open reading frame
- describe composition or plurality of vectors
- specify promoters and transcription termination sequences
- describe ribozymes
- introduce RNA polymerase II promoter
- describe vectors for reassortant
- provide method to prepare influenza virus
- isolate virus from cell
- describe method to select for influenza viruses
- provide isolated viral polypeptides and methods of use

## DETAILED DESCRIPTION

### Definitions

- define "isolated"
- define "substantially purified"
- define "substantially free"
- define "recombinant"
- define "heterologous"
- define "sequence comparison"

### Influenza B Virus Structure and Propagation

- describe influenza B virus life cycle

### Influenza B Viruses of the Invention

- describe mutations increasing replicative ability
- describe use of mutations in vaccine production

### Cell Lines that can be Used in the Present Invention

- list cell lines for vaccine production
- describe characterization of cell lines

### Influenza Vaccines

- describe vaccine composition
- describe purification of viruses
- describe subunit vaccine preparation
- describe split vaccine preparation
- describe inactivated vaccines
- describe live attenuated virus vaccines
- describe multivalent vaccines

### Pharmaceutical Compositions

- describe composition formulation
- describe adjuvants and excipients
- describe chemotherapeutic compounds

### Pharmaceutical Purposes

- describe prophylactic administration
- describe therapeutic administration

### Pharmaceutical Administration

- introduce vaccine composition
- describe administration methods
- outline dosage regimens
- specify effective amounts

### Exemplary Embodiments

- define recombinant influenza B virus with enhanced replication in MDCK cells
- specify amino acid residues in HA, NA, NP, M1, BM2, and NS1 for enhanced replication
- define recombinant influenza B virus with enhanced replication in Vero cells
- specify amino acid residues in HA, NA, NP, M1, BM2, and NS1 for enhanced replication
- define recombinant influenza B virus with enhanced replication in B/Yamagata-lineage
- specify amino acid residues in HA, NA, NP, M1, BM2, and NS1 for enhanced replication
- define recombinant influenza B virus with enhanced replication in B/Victoria-lineage
- specify amino acid residues in HA, NA, NP, M1, BM2, and NS1 for enhanced replication
- define recombinant influenza B virus with multiple amino acid residues
- specify combinations of amino acid residues in HA, NA, NP, M1, BM2, and NS1
- define recombinant influenza B virus with two or more selected amino acid residues
- specify combinations of amino acid residues in PA, NP, M1, BM2, and NS1
- introduce example of recombinant influenza B virus with multiple amino acid residues
- describe yield of vaccine viruses in different host cells
- introduce random mutagenesis of internal genes of B/Yamagata/1/73
- describe construction of plasmids and plasmid libraries
- outline materials and methods for cell growth and plasmid construction
- generate virus libraries
- evaluate viral growth kinetics
- determine hemagglutination titers
- concentrate and purify viruses
- determine total protein yield
- deglycosylate viral proteins
- analyze viral proteins by SDS/PAGE
- conduct virulence studies in mice
- evaluate genetic stability of vaccine backbones
- perform minireplicon, VLP budding, and IFN antagonist assays
- introduce ethics and biosafety
- describe virus library screens for high-yield variants in MDCK cells
- motivate selection of high-yield variants
- describe potential combinatorial effects of mutations
- describe virus library screens for high-yield variants in Vero cells
- motivate selection of high-yield vaccine virus candidates
- evaluate high-yield vaccine virus backbones with different influenza B virus HA and NA genes
- exchange HY(Yam) and HY(Vic) backbones
- compare influenza A and B virus vaccine backbones
- evaluate total viral protein yield and HA content
- describe results of virus library screens for high-yield variants in MDCK cells
- describe results of virus library screens for high-yield variants in Vero cells
- describe results of evaluation of high-yield vaccine virus backbones
- describe results of comparison of influenza A and B virus vaccine backbones
- design experimental approach
- test virulence of vaccine viruses in mice
- assess genetic stability of vaccine backbones
- determine contribution of individual vRNAs to high-yield properties
- evaluate effect of individual mutations on viral replication complex
- analyze effect of individual mutations on composition of virus-like particles
- assess effect of mutation in HY(Yam) NS1 protein on IFN antagonist activity
- discuss development of high-yield influenza B vaccine backbones
- compare results with previous studies
- evaluate importance of high virus and HA yields for vaccine production
- analyze rarity of amino acid changes in HY(Yam) and HY(Vic) among natural influenza B viruses
- discuss potential mechanisms of yield-enhancing mutations
- summarize development of influenza B vaccine virus backbones

